Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-08
2006-08-08
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S253000
Reexamination Certificate
active
07087631
ABSTRACT:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
REFERENCES:
patent: 5049572 (1991-09-01), Scherrer et al.
patent: 5232937 (1993-08-01), Makovec et al.
patent: 5284954 (1994-02-01), Wittenberger
patent: 5364869 (1994-11-01), De
patent: 5663357 (1997-09-01), Teng et al.
patent: 5874593 (1999-02-01), Ushio
patent: 5976576 (1999-11-01), Makovec et al.
patent: 6191136 (2001-02-01), Marban
patent: 6191289 (2001-02-01), Ushio
patent: 6277998 (2001-08-01), Ushio
patent: 6281222 (2001-08-01), Salzman et al.
patent: 6297261 (2001-10-01), Christophersen et al.
patent: 6388088 (2002-05-01), Sidduri
patent: 6417393 (2002-07-01), Christophersen et al.
patent: 6569862 (2003-05-01), Marban
patent: 6696479 (2004-02-01), Van Der Schaaf et al.
patent: 6706749 (2004-03-01), Dahl et al.
patent: 2002/0032210 (2002-03-01), Pinto et al.
patent: 2002/0037905 (2002-03-01), Dahl et al.
patent: 2003/0186998 (2003-10-01), Marban
patent: 2003/0229120 (2003-12-01), Olsen et al.
patent: 2004/0019208 (2004-01-01), Nivorozhkin et al.
patent: 0638553 (1994-07-01), None
patent: 10025294 (1998-01-01), None
patent: WO 90/09989 (1990-09-01), None
patent: WO 93/16053 (1993-08-01), None
patent: WO 98/58522 (1998-12-01), None
patent: WO 99/24038 (1999-05-01), None
patent: WO 99/24442 (1999-05-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 00/24707 (2000-05-01), None
patent: WO 00/28979 (2000-05-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 01/66098 (2001-09-01), None
patent: WO 01/85705 (2001-11-01), None
patent: WO 02/00647 (2002-01-01), None
Oda et al., Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD, Science. May 26, 1989;244(4907):974-6.
Tan et al. ,Xanthine oxidase activity in the circulation of rats following hemorrhagic shock, Free Radic Biol Med. Oct. 1993;15(4):407-14.
McCord J. M., Oxygen-derived free radicals in postischemic tissue injury, N Engl J Med. Jan. 17, 1985;312(3):159-63.
Miesel et al., “Effects of allopurinol on in vivo suppression of arhtritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood”, Inflammation. Dec. 1994;18(6):597-612.
Engerson et al., Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues,J Clin Invest. Jun. 1987;79(6):1564-70.
Akaide et al., Dependence on O2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice,J Clin Invest. Mar. 1990;85(3):739-45.
Ketal et al., Plasma hypoxanthine and exercise.Am Rev Respir Dis.Jul. 1987;136(1):98-101.
Mohacsi et al., Neutrophils obtained from obliterative atherosclerotic patients exhibit enhanced resting respiratory burst and increased degranulation in response to various stimuli, Biochim Biophys Acta. Aug. 23, 1996;1316(3):210-6.
Friedl et al., Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol. Mar. 1990;136(3):491-5.
Friedl et al. Roles of histamine, complement and xanthine oxidase in thermal injury of skin.Am J Pathol. Jul. 1989;135(1):203-17.
Parks et al., Role of oxygen free radicals in shock, ischemia, and organ preservation.Surgery. Sep. 1983;94(3):428-32.
Demling et al., Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes.Am Rev Respir Dis. Nov. 1992;148(5 Pt 1):1272-8.
Chambers et al., Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol. Feb. 1985;17(2):145-52.
Deltch et al., Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation.Surgery. Aug. 1988;104(2):191-8.
Mayumi et al., Zonal heterogeneity of hepatic injury following shock/resuscitation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis. Shock. May 1996;5(5):324-32.
Flynn et al., Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock.J Trauma. Dec. 1994;37(6):958-81.
Zollei, I., Experimental study of hypovolaemic shock-induced gastric mucosal lesions in the rat. Ann Acad Med Singapore. Jan. 1999;28(1):85-9.
Flynn et al., Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock. J Trauma. Dec. 1994;37(6):956-61.
Modelska et al., Inhibition of beta-adrenergic-dependent alveolar epithelial clearance by oxidant mechanisms after hemorrhagic shock. Am J Physiol. May 1999;276(5 Pt 1):L844-57.
Flynn et al., Xanthine oxidase inhibition prevents mesenteric blood flow deficits after resuscitated hemorrhagic shock by preserving endothelial function. J Surg Res. Mar. 1997;68(2):175-80.
Mannion et al., Role of xanthine oxidase inhibition in survival from hemorrhagic shock. Circ Shock. Jan. 1994;42(1):39-43.
Cunningham and Keaveny, Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock. Eur. Surg Res. 1978;10(3):305-13.
Youn et al., Oxidants and the pathophysiology of burn and smoke inhalation injury. Free Radic Biol Med. 1992;12(5):409-15.
Deitch et al., A study of the relationship among survival, gut-origin sepsis, and bacterial translocation in a model of systemic inflammation.J Trauma. Feb. 1992;32(2):141-7.
Anderson et al., Hypovolemic shock promotes neutrophil sequestration in lungs by a xanthine oxidase-related mechanism. J Appl Physiol. Nov. 1991;71(5):1862-5.
Pogetti et al., Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J Trauma Jun. 1992;32(6):723-7; discussion 727-8.
Nielsen et al., Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta acclusion and reperfusion in rabbits. J Thorac Cardiovasc Surg. Sep. 1995;110(3):715-22.
Schwartz et al., Xanthine oxidase-derived oxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Mol Biol. Apr. 1995;12(4):434-40.
Crowell et al., Effect of allopurinol on hemorrhagic shock. Am J Physiol. 1969 Apr.;216(4):744-8.
Linder et al., Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest. Aug. 1999;79(8):967-74.
Saksela et al., Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol. Neonate. Oct. 1998;74(4):274-80.
Battelli et al., Determination of xanthine oxidase in human serum by a competitive enzyme-linked mmunosorbent assay (ELISA). Clin Chim Acta. Mar. 1999;281(1-2):147-58.
Houston et al., Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. Feb. 19, 1999;274(8):4985-94.
Fox et al., Immunohistochemical localization of xanthine oxidase in human retina. Free Radic Biol Med. Apr. 1998;24(6):900-5.
Rouquette et al., Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett. Apr. 24, 1998;426(3):397-401.
Cardillo et al., Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. Jul. 1997;30(1 Pt 1):57-63.
Page et al., Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta. Jul. 23, 1998;1381(2):191-202.
Zhang et al., Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res. Commun. Aug. 28, 1998;249(3):767-72.
Trujillo et al., Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem. Apr. 3, 1998;273(14):7828-34.
Goldfinger, S.E., Treatment of gout. N Engl J Med. Dec. 2, 1971;285(23):13
Nivorozhkin Alex
Ram Siya
Southan Garry
Van Duzer John
Zeng Qi
Inotek Pharmaceuticals Corporation
Solola Taofiq
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Aryltetrazole compounds, and compositions thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryltetrazole compounds, and compositions thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryltetrazole compounds, and compositions thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3642236